BioNTech SE - ADR vs J B Hunt Transport Services Inc — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while J B Hunt Transport Services Inc trades at $275.51 (market cap $24.92B). The key difference: BioNTech SE - ADR and J B Hunt Transport Services Inc are close in size by market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | JBHT | |
|---|---|---|
Market Cap | $23.31B | $24.92B |
Sector | Health | Industrials |
52-Week High | $119.34 | $298.41 |
52-Week Low | $83.89 | $130.65 |
Enterprise Value | $6.60B | $26.06B |
Dividend Yield | — | 0.68% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
JBHT trades at $275.5, up 3.52% today, with a bearish technical signal but strong analyst consensus. The company reported revenue of $12.0B in 2025, with net income of $598.28M and a 5.31% net margin. Recent earnings have consistently beaten estimates, and the company announced a $0.45 dividend payable in August 2026. Cash flow from operations remains robust at $1.68B in 2025, though net cash flow was slightly negative.
The outlook is positive with a consensus price target of $299.82, implying 8.8% upside. Risks include competitive pressures and macroeconomic volatility, but strong institutional ownership and a buy rating from 57.8% of analysts support a favorable view. The stock's valuation multiples are elevated, but earnings growth and intermodal demand recovery provide catalysts.
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →